%0 Journal Article %A Victoria C. Yan %A Sunada Khadka %A Kenisha Arthur %A Cong-Dat Pham %A Matthew J. Yan %A Alexander J. Yan %A Jeffrey J. Ackroyd %A Dimitra K. Georgiou %A Florian L. Muller %T Pharmacokinetics of Orally Administered GS-441524 in Dogs %D 2021 %R 10.1101/2021.02.04.429674 %J bioRxiv %P 2021.02.04.429674 %X Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury®) remains contentious. We previously described the pharmacokinetic, pharmacodynamic and toxicological rationales on the greater suitability of its parent nucleoside, GS-441524, for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations approximately 24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.Competing Interest StatementThe authors have declared no competing interest. %U https://www.biorxiv.org/content/biorxiv/early/2021/02/22/2021.02.04.429674.full.pdf